Grund Nicholas
Chief Commercial Officer
Grund Nicholas has filed 2 SEC Form 4 filings (3 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Feb 4, 2026.
On the most recent filing, Grund Nicholas is listed as Chief Commercial Officer at Akebia Therapeutics, Inc. Inside the rolling window, Grund Nicholas reported no open-market purchases and 1 open-market sale totaling $118K in AKBA.
Companies traded
Other insiders at AKBA
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$118K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Grund Nicholas made?
Grund Nicholas has filed 2 SEC Form 4 filings (3 transaction rows) across 1 company since 2026.
Which companies does Grund Nicholas trade?
Grund Nicholas has filed SEC Form 4 disclosures for 1 company, including AKBA.
When was Grund Nicholas's most recent SEC Form 4 filing?
Grund Nicholas's most recent SEC Form 4 filing on Tracefour is dated Feb 4, 2026.
What is Grund Nicholas's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Grund Nicholas is listed as Chief Commercial Officer.
What is Grund Nicholas's total buy and sell value in the current window?
Inside the rolling retention window, Grund Nicholas bought $0 and sold $118K based on SEC Form 4 filings.
What was Grund Nicholas's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 84,829 AKBA shares on 2026-02-02, worth $118K, per SEC Form 4 filings.